Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease

Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.

Katsuyoshi Matsuoka
Shunsuke Hamada
Mikiko Shimizu
Kosaku Nanki
Shinta Mizuno
Hiroki Kiyohara
Mari Arai
Shinya Sugimoto
Yasushi Iwao
Haruhiko Ogata
Tadakazu Hisamatsu
Makoto Naganuma
Takanori Kanai
Mayumi Mochizuki
Masayuki Hashiguchi

January 2018

Since anti-tumor necrosis factor (TNF)-α agents (TNF-α inhibitors) induce both clinical response and...

A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.

Louis, E
Vermeire, S
Rutgeerts, P
De Vos, M
Van Gossum, A
Pescatore, P.
Fiasse, René
Pelckmans, P
Reynaert, H
D'Haens, G
Malaise, M
Belaiche, J

January 2002

Two-thirds to three-fourths of patients with either refractory luminal or fistulizing Crohn disease ...

ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases

김승원
박지혜
정은석
천재희

January 2019

BACKGROUND AND AIM: Infliximab has been widely prescribed for treating inflammatory bowel disease ...

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease

Ternant, David
Berkane, Zahir
Picon, Laurence
Gouilleux-Gruart, Valérie
Colombel, Jean-Frédéric
Allez, Matthieu
Louis, Edouard
Paintaud, Gilles

May 2015

International audienceInfliximab is a monoclonal anti-tumor necrosis factor-α (anti-TNFα) antibody t...

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.

Ternant, David
Berkane, Zahir
Picon, Laurence
Gouilleux-Gruart, Valerie
Colombel, Jean-Frederic
Allez, Matthieu
Louis, Edouard
Paintaud, Gilles

January 2015

BACKGROUND AND OBJECTIVES: Infliximab is a monoclonal anti-tumor necrosis factor-alpha (anti-TNFalph...

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease

Louis, Edouard
El Ghoul, Z.
Vermeire, S.
Dall'Ozzo, S.
Rutgeerts, P.
Paintaud, G.
Belaiche, Jacques
De Vos, M.
Van Gossum, A.
Colombel, J. F.
Watier, H.

March 2004

AIM: To test the hypothesis of an association between polymorphism in FCGR3A (the gene coding for Fc...

Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study.

Louis, Edouard
Watier, Herve E
Schreiber, Stefan
Hampe, Jochen
Taillard, Francois
Olson, Allan
Thorne, Nicole
Zhang, Hongyan
Colombel, Jean-Frederic

January 2006

Recently, it has been shown that FCGR3A-158 gene polymorphism is associated with biological and poss...

No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease.

Willot, Stéphanie
Vermeire, Séverine
Ohresser, Marc
Rutgeerts, Paul
Paintaud, Gilles
Belaiche, Jacques
De Vos, M
Van Gossum, André
Franchimont, Denis
Colombel, Jean Frédéric
Watier, Hervé
Louis, Edouard

January 2006

We recently showed an association between the FCGR3A V/F polymorphism and the biological response [a...

Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients

Gilles Thibault
Gilles Paintaud
Hsueh Cheng Sung
Laurie Lajoie
Edouard Louis
the GETAID
Celine Desvignes
Hervé Watier
Valérie Gouilleux-Gruart
David Ternant

June 2021

The FcγRIIA/CD32A is mainly expressed on platelets, myeloid and several endothelial cells. Its affin...

Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn’s Disease

Urabe, Shigetoshi
Isomoto, Hajime
Ishida, Tetsuya
Maeda, Kazumi
Inamine, Tatsuo
Kondo, Shinji
Higuchi, Norihide
Sato, Kayoko
Uehara, Ryohei
Yajima, Hiroyuki
Machida, Haruhisa
Chen, Chun Chuan
Fukuda, Yasuhiro
Takeshima, Fuminao
Nakao, Kazuhiko
Tsukamoto, Kazuhiro

January 2015

Background. We aimed to identify certain genes related to response to infliximab (IFX) and biomarker...

Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients.

Thibault, Gilles
Paintaud, Gilles
Sung, Hsueh Cheng
Lajoie, Laurie
Louis, Edouard
The Getaid,
Desvignes, Celine
Watier, Hervé
Gouilleux-Gruart, Valérie
Ternant, David

January 2021

peer reviewedThe FcγRIIA/CD32A is mainly expressed on platelets, myeloid and several endothelial cel...

Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease

December 2021

9noInfliximab is commonly used in inflammatory bowel disease (IBD), however, differences in clinical...

Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis

Montes, A.
Perez-Pampin, E.
Narváez, J.
Cañete, J. D.
Navarro-Sarabia, F.
Moreira, V.
Fernández-Nebro, A.
Del Carmen Ordóñez, M.
De La Serna, A. R.
Magallares, B.
Vasilopoulos, Y.
Sarafidou, T.
Caliz, R.
Ferrer, M. A.
Joven, B.
Carreira, P.
Gómez-Reino, J. J.
Gonzalez, A.

January 2014

OBJECTIVES: We aimed to assess a functional polymorphism in FCGR2A H131R, for association with the t...

Pharmacogenetic biomarkers of response in Crohn's disease.

Linares-Pineda, T M
Cañadas-Garre, M
Sánchez-Pozo, A
Calleja-Hernández, M Á

June 2017

Crohn's disease (CD) is a chronic condition, which affects the immune system. It can also affect any...

No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease

Willot, S.
Vermeire, S.
Ohresser, M.
Rutgeerts, P.
Paintaud, G.
Belaiche, Jacques
De Vos, M.
Van Gossum, A.
Franchimont, D.
Colombel, J. F.
Watier, H.
Louis, Edouard

January 2006

We recently showed an association between the FCGR3A V/F polymorphism and the biological response [a...

Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.

Katsuyoshi Matsuoka
Shunsuke Hamada
Mikiko Shimizu
Kosaku Nanki
Shinta Mizuno
Hiroki Kiyohara
Mari Arai
Shinya Sugimoto
Yasushi Iwao
Haruhiko Ogata
Tadakazu Hisamatsu
Makoto Naganuma
Takanori Kanai
Mayumi Mochizuki
Masayuki Hashiguchi

January 2018

Since anti-tumor necrosis factor (TNF)-α agents (TNF-α inhibitors) induce both clinical response and...

A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.

Louis, E
Vermeire, S
Rutgeerts, P
De Vos, M
Van Gossum, A
Pescatore, P.
Fiasse, René
Pelckmans, P
Reynaert, H
D'Haens, G
Malaise, M
Belaiche, J

January 2002

Two-thirds to three-fourths of patients with either refractory luminal or fistulizing Crohn disease ...

ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases

김승원
박지혜
정은석
천재희

January 2019

BACKGROUND AND AIM: Infliximab has been widely prescribed for treating inflammatory bowel disease ...

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease

Ternant, David
Berkane, Zahir
Picon, Laurence
Gouilleux-Gruart, Valérie
Colombel, Jean-Frédéric
Allez, Matthieu
Louis, Edouard
Paintaud, Gilles

May 2015

International audienceInfliximab is a monoclonal anti-tumor necrosis factor-α (anti-TNFα) antibody t...

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.

Ternant, David
Berkane, Zahir
Picon, Laurence
Gouilleux-Gruart, Valerie
Colombel, Jean-Frederic
Allez, Matthieu
Louis, Edouard
Paintaud, Gilles

January 2015

BACKGROUND AND OBJECTIVES: Infliximab is a monoclonal anti-tumor necrosis factor-alpha (anti-TNFalph...

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease

Louis, Edouard
El Ghoul, Z.
Vermeire, S.
Dall'Ozzo, S.
Rutgeerts, P.
Paintaud, G.
Belaiche, Jacques
De Vos, M.
Van Gossum, A.
Colombel, J. F.
Watier, H.

March 2004

AIM: To test the hypothesis of an association between polymorphism in FCGR3A (the gene coding for Fc...

Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study.

Louis, Edouard
Watier, Herve E
Schreiber, Stefan
Hampe, Jochen
Taillard, Francois
Olson, Allan
Thorne, Nicole
Zhang, Hongyan
Colombel, Jean-Frederic

January 2006

Recently, it has been shown that FCGR3A-158 gene polymorphism is associated with biological and poss...

No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease.

Willot, Stéphanie
Vermeire, Séverine
Ohresser, Marc
Rutgeerts, Paul
Paintaud, Gilles
Belaiche, Jacques
De Vos, M
Van Gossum, André
Franchimont, Denis
Colombel, Jean Frédéric
Watier, Hervé
Louis, Edouard

January 2006

We recently showed an association between the FCGR3A V/F polymorphism and the biological response [a...

Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients

Gilles Thibault
Gilles Paintaud
Hsueh Cheng Sung
Laurie Lajoie
Edouard Louis
the GETAID
Celine Desvignes
Hervé Watier
Valérie Gouilleux-Gruart
David Ternant

June 2021

The FcγRIIA/CD32A is mainly expressed on platelets, myeloid and several endothelial cells. Its affin...

Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn’s Disease

Urabe, Shigetoshi
Isomoto, Hajime
Ishida, Tetsuya
Maeda, Kazumi
Inamine, Tatsuo
Kondo, Shinji
Higuchi, Norihide
Sato, Kayoko
Uehara, Ryohei
Yajima, Hiroyuki
Machida, Haruhisa
Chen, Chun Chuan
Fukuda, Yasuhiro
Takeshima, Fuminao
Nakao, Kazuhiko
Tsukamoto, Kazuhiro

January 2015

Background. We aimed to identify certain genes related to response to infliximab (IFX) and biomarker...

Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients.

Thibault, Gilles
Paintaud, Gilles
Sung, Hsueh Cheng
Lajoie, Laurie
Louis, Edouard
The Getaid,
Desvignes, Celine
Watier, Hervé
Gouilleux-Gruart, Valérie
Ternant, David

January 2021

peer reviewedThe FcγRIIA/CD32A is mainly expressed on platelets, myeloid and several endothelial cel...

Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease

December 2021

9noInfliximab is commonly used in inflammatory bowel disease (IBD), however, differences in clinical...

Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis

Montes, A.
Perez-Pampin, E.
Narváez, J.
Cañete, J. D.
Navarro-Sarabia, F.
Moreira, V.
Fernández-Nebro, A.
Del Carmen Ordóñez, M.
De La Serna, A. R.
Magallares, B.
Vasilopoulos, Y.
Sarafidou, T.
Caliz, R.
Ferrer, M. A.
Joven, B.
Carreira, P.
Gómez-Reino, J. J.
Gonzalez, A.

January 2014

OBJECTIVES: We aimed to assess a functional polymorphism in FCGR2A H131R, for association with the t...

Pharmacogenetic biomarkers of response in Crohn's disease.

Linares-Pineda, T M
Cañadas-Garre, M
Sánchez-Pozo, A
Calleja-Hernández, M Á

June 2017

Crohn's disease (CD) is a chronic condition, which affects the immune system. It can also affect any...

No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease

Willot, S.
Vermeire, S.
Ohresser, M.
Rutgeerts, P.
Paintaud, G.
Belaiche, Jacques
De Vos, M.
Van Gossum, A.
Franchimont, D.
Colombel, J. F.
Watier, H.
Louis, Edouard

January 2006

We recently showed an association between the FCGR3A V/F polymorphism and the biological response [a...

Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.

Katsuyoshi Matsuoka
Shunsuke Hamada
Mikiko Shimizu
Kosaku Nanki
Shinta Mizuno
Hiroki Kiyohara
Mari Arai
Shinya Sugimoto
Yasushi Iwao
Haruhiko Ogata
Tadakazu Hisamatsu
Makoto Naganuma
Takanori Kanai
Mayumi Mochizuki
Masayuki Hashiguchi

January 2018

Since anti-tumor necrosis factor (TNF)-α agents (TNF-α inhibitors) induce both clinical response and...

A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.

Louis, E
Vermeire, S
Rutgeerts, P
De Vos, M
Van Gossum, A
Pescatore, P.
Fiasse, René
Pelckmans, P
Reynaert, H
D'Haens, G
Malaise, M
Belaiche, J

January 2002

Two-thirds to three-fourths of patients with either refractory luminal or fistulizing Crohn disease ...

ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases

김승원
박지혜
정은석
천재희

January 2019

BACKGROUND AND AIM: Infliximab has been widely prescribed for treating inflammatory bowel disease ...

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease

Abstract

Extracted data

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease

Abstract

Extracted data

Related items

Related items